---
figid: PMC10299185__IJNS-09-00031-g001
figtitle: Metabolic pathway involved in FD
organisms:
- NA
organisms_ner:
- NA
pmcid: PMC10299185
filename: PMC10299185__IJNS-09-00031-g001.jpg
figlink: /pmc/articles/PMC10299185/figure/F1
number: F1
caption: Metabolic pathway involved in FD. αGalA deficiency, due to the GLA gene pathogenic
  variant, leads to lysosomal storage of globotriaosylcramide (Gb3) and related glycosphingolipids
  (for example, its deacylated form, globotriaosylsphingosine or lysoGb3)
papertitle: 'Newborn Screening for Fabry Disease: Current Status of Knowledge'
reftext: Vincenza Gragnaniello, et al. Int J Neonatal Screen. 2023 Jun;9(2).
year: '2023'
doi: 10.3390/ijns9020031
journal_title: International Journal of Neonatal Screening
journal_nlm_ta: Int J Neonatal Screen
publisher_name: MDPI
keywords: Fabry disease | newborn screening | lysosomal storage disease | digital
  microfluidics | tandem mass spectrometry | second tier test | LysoGb3
automl_pathway: 0.930276
figid_alias: PMC10299185__F1
figtype: Figure
redirect_from: /figures/PMC10299185__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC10299185__IJNS-09-00031-g001.html
  '@type': Dataset
  description: Metabolic pathway involved in FD. αGalA deficiency, due to the GLA
    gene pathogenic variant, leads to lysosomal storage of globotriaosylcramide (Gb3)
    and related glycosphingolipids (for example, its deacylated form, globotriaosylsphingosine
    or lysoGb3)
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Glycosphingolipids
  - NUCLEUS
  - Gal
  - HO-
  - Glu
  - Cer
---
